Adrenocortical carcinoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}}
!Laboratory tests
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory tests}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Adrenal adenoma
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Adrenal adenoma
Line 22: Line 22:
*  
*  
|
|
* Round and homogeneous density, smooth contour and sharp margination [15]
* Round and homogeneous density, smooth contour and sharp margination
* Diameter less than 4 cm, unilateral location
* Diameter less than 4 cm, unilateral location
* Low unenhanced CT attenuation values (<10 HU) (image 1)
* Low unenhanced CT attenuation values (<10 HU)  
* Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
* Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
* Isointensity with liver on both T1 and T2 weighted MRI sequences
* Isointensity with liver on both T1 and T2 weighted MRI sequences
* Chemical shift evidence of lipid on MRI
* Chemical shift: evidence of lipid on MRI
|
|
|-
|-
Line 35: Line 35:
|
|
* Irregular shape
* Irregular shape
* Inhomogeneous density because of central areas of low attenuation due to tumor necrosis (image 4)
* Inhomogeneous density because of central areas of low attenuation due to tumor necrosis
* Tumor calcification
* Tumor calcification
* Diameter usually >4 cm
* Diameter usually >4 cm
Line 47: Line 47:
|
|
* Serum DHEAS
* Serum DHEAS
* Measures of clinicallyindicated
* Measures of clinically indicated steroid
* steroid
|-
|-
|
|

Revision as of 15:28, 24 September 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma differential diagnosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma differential diagnosis

CDC on Adrenocortical carcinoma differential diagnosis

Adrenocortical carcinoma differential diagnosis in the news

Blogs on Adrenocortical carcinoma differential diagnosis

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]Ahmad Al Maradni, M.D. [3]

Overview

Adrenocortical carcinoma must be differentiated from other diseases such as adrenocortical adenoma, renal cell carcinoma, adrenal medullary tumors, and hepatocellular carcinoma.

Differentiating Adrenal Carcinoma from other Diseases

Adrenocortical carcinoma should be differentiated from:

Differential Diagnosis Clinical picture Imagings Laboratory tests
Adrenal adenoma
  • Round and homogeneous density, smooth contour and sharp margination
  • Diameter less than 4 cm, unilateral location
  • Low unenhanced CT attenuation values (<10 HU)
  • Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
  • Isointensity with liver on both T1 and T2 weighted MRI sequences
  • Chemical shift: evidence of lipid on MRI
Adrenocortical carcinoma
  • Mass effect symptoms; symptoms related to excess glucocorticoid, mineralocorticoid, androgen, or estrogen secretion
  • Irregular shape
  • Inhomogeneous density because of central areas of low attenuation due to tumor necrosis
  • Tumor calcification
  • Diameter usually >4 cm
  • Unilateral location
  • High unenhanced CT attenuation values (>20 HU)
  • Inhomogeneous enhancement on CT with intravenous contrast
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • Hypointensity compared with liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI
  • High standardized uptake value (SUV) on FDG-PET-CT study
  • Evidence of local invasion or metastases
  • Serum DHEAS
  • Measures of clinically indicated steroid
Cushing's syndrome
  • Imaging may show adenoma if presents
Pheochromocytoma
  • Increased attenuation on nonenhanced CT (>20 HU)
  • Increased mass vascularity (image 2)
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • High signal intensity on T2 weighted MRI (image 3)
  • Cystic and hemorrhagic changes
  • Variable size and may be bilateral
Adrenal metastasis
    • Symptoms and signs of primary malignancy especially lung cancer.
    • General constitutional symptoms:
    • Fever
    • Fatigue
    • Weight loss
  • Irregular shape and inhomogeneous nature
  • Tendency to be bilateral
  • High unenhanced CT attenuation values (>20 HU) and enhancement with intravenous contrast on CT
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • Isointensity or slightly less intense than the liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI (representing an increased water content)
  • Elevated standardized uptake value on FDG-PET scan

References